2025.10.16 18:15
Inje University Ilsan Paik Hospital held a ceremony on October 15 in its sixth-floor seminar room to mark the completion of the 2024-26 Lee Jong-wook Fellowship Clinical Program, recognizing ten healthcare professionals from Laos. The event, attended by Hospital President Won Joo Choi and other key figures, celebrated the participants’ achievements after an intensive five-month training program.The cohort, comprising seven physicians and three nurses selected from Laos’ national medical and educational institutions, underwent tailored clinical training at Ilsan Paik Hospital. The curriculum
2025.10.16 18:13
GC Green Cross Medical Foundation, a leading South Korean medical institution, has successfully transferred advanced cytogenetic testing technology to BioLAB, a diagnostic center in Bahrain, marking a significant step in exporting Korean medical expertise to the Middle East.The technology transfer, formalized through a contract signed in March, enables BioLAB to independently conduct chromosome analysis and fluorescence in situ hybridization (FISH) tests. Over 16 weeks, GC Green Cross provided an intensive training program to equip BioLAB’s staff with the necessary skills. The foundation also
2025.10.16 18:11
On October 16, Rokit Healthcare (376900), a South Korean biomedical company, announced that its AI-driven autologous tissue-regeneration therapy for diabetic foot ulcers had been officially approved for reimbursement under public insurance at a major U.S. tertiary-care hospital outpatient department (HOPD). This marks the first time an AI-based regenerative treatment has been recognized within the U.S. public insurance framework, specifically under the Current Procedural Terminology (CPT) code system.Rokit’s diabetic foot treatment, which leverages AI to personalize tissue regeneration, achie
2025.10.13 17:07
Celltrion, a South Korean biopharmaceutical company, has launched its autoimmune disease treatment Aptozma (tocilizumab) in the U.S., marking a significant step in its global market strategy. The drug, initially introduced as an intravenous (IV) formulation, will soon be followed by a subcutaneous (SC) version, expanding its accessibility to patients.Aptozma is priced approximately 35% lower than its originator drug at wholesale acquisition cost (WAC), a strategic move by Celltrion to balance affordability with profitability. The biosimilar works by inhibiting interleukin-6 (IL-6), a cytokine
2025.10.13 17:05
[Physician's Column] By Dong Yeob Lee, Director of Neurosurgery, Champodnamu HospitalAs autumn settles in, the sharp temperature swings between morning and evening, coupled with cooler air, can subtly affect the body’s blood circulation and muscle health. For middle-aged and older adults, these seasonal changes often exacerbate vulnerabilities, potentially triggering conditions like lumbar disc herniation, spinal stenosis, sciatica, or even cerebrovascular disorders.When temperatures drop and daily temperature fluctuations widen, muscles tend to contract, and blood flow diminishes. This envir
2025.10.13 17:04
[Physician's Column] By Ho Dong Moon, MD, Vice Director of Clinical Services, Park Ae Hospital (Orthopedic Surgery Specialist) Patients visiting hospitals for knee pain often ask, “Will surgery require a large incision?” In the past, treating or examining the inside of a joint meant making wide incisions through skin and muscle. This approach led to significant post-surgical pain and prolonged recovery times. Today, a small camera called an arthroscope—roughly the thickness of a finger—allows doctors to directly visualize the inside of a joint and perform necessary treatments. The arthro
2025.10.10 15:48
As flu season approaches, health experts are urging teenagers and adults in their 30s to prioritize vaccinations to curb the spread of influenza, a potentially severe respiratory illness. According to South Korea’s Health Insurance Review and Assessment Service, in 2024, teenagers accounted for over 600,000 flu cases, the highest among all age groups, while adults in their 30s followed with approximately 350,000 cases, second only to infants. The data underscores the vulnerability of these groups, driven by frequent group interactions among teens and active social and caregiving responsibilit
2025.10.10 15:46
Shin Dong-bin, chairman of South Korea’s Lotte Group, visited the Lotte Biologics bio-campus in Syracuse, New York, to review its production facilities and encourage employees. This marked his first visit since the campus began full-scale operations of its antibody-drug conjugate (ADC) production facility. During the visit, Shin was briefed on local operations and inspected the production process, accompanied by Lotte Biologics CEO James Park and Global Strategy Head Yoo-yeol Shin.The visit comes as the U.S. government signals plans to impose 100% tariffs on imported pharmaceuticals, raising2025.10.10 15:25
Celltrion, a South Korean biopharmaceutical company, announced on October 10, 2025, that its biosimilar drug Idenzent (CT-P42), a counterpart to the blockbuster eye treatment Eylea (aflibercept), has received approval from the U.S. Food and Drug Administration (FDA). The approval marks a significant milestone for Celltrion, enabling the company to enter the world’s largest pharmaceutical market with a drug already authorized in South Korea, Europe, and Australia.The FDA approved Idenzent in two formulations—vials and pre-filled syringes (PFS). The biosimilar is approved for the full range of
2025.09.30 22:55
In a major advance for rare disease research, a patient who endured unexplained immunodeficiency, developmental disorders, and lymphoma for 16 years has finally received a genetic diagnosis. A collaborative team from Seoul National University Hospital and Chung-Ang University has, for the first time, established that mutations in the BRF2 gene can directly cause such conditions, while also uncovering the underlying disease mechanisms—a world first.The study was jointly led by Professor Jong-Hee Chae's team at Seoul National University Hospital and Professor Keun Pil Kim's team at Chung-Ang Un
2025.09.30 22:52
SEOUL, South Korea — Yonsei Severance Hospital announced the opening of the Min Yoongi Treatment Center on September 30, a specialized facility for children with autism spectrum disorder (ASD). The center was established with a 50 billion won ($38 million) donation from BTS member Suga, whose real name is Min Yoongi.The opening ceremony, held at the hospital’s Jejung Hall on the first floor, was attended by key figures, including Yonsei University President Dong-sup Yoon, Yonsei Medical Center Director Ki-chang Keum, Severance Hospital Director Kang-young Lee, Children’s Hospital Director H
2025.09.30 22:49
[Physician's Column] By Seung Yi Kim, MD, Director of Seoul Barun Urology Clinic, Bupyeong BranchAs seasons change, fluctuating temperatures and increased sweating can deplete the body’s fluids, leading to a host of health concerns. Among these, kidney stones—a common urological condition—show a marked increase in incidence. These hard deposits, known medically as renal calculi, form in the kidneys, ureters, or bladder, triggering flank pain, blood in the urine (hematuria), and urinary difficulties that can significantly diminish quality of life.Kidney stones arise when substances like calc
2025.09.30 22:38
YOKOHAMA, Japan — Samsung Biologics, a leading South Korean contract development and manufacturing organization (CDMO), will participate in Bio Japan 2025, Asia’s largest biotechnology and pharmaceutical exhibition, from October 8 to 10 in Yokohama, Japan. The company announced it will operate a standalone booth for the first time, marking its third consecutive appearance at the event.Bio Japan, established in 1986, is a premier industry gathering that spans biopharmaceuticals, regenerative medicine, and digital healthcare. This year’s event expects participation from 1,139 companies and mo
주소: (07327) 서울특별시 영등포구 국제금융로2길 17 시티플라자 421호 | 전화: 02-313-2382 | 이메일: press@hinews.co.kr
제호: hinews(하이뉴스) | 등록번호: 서울,아04641 | 발행일: 2017. 8. 4
대표이사: 김국주 | 발행인: 굿닥터홀딩스 주식회사 김국주 | 편집인: 이상호 | 청소년보호책임자: 임혜정
Hinews의 모든 콘텐츠는 저작권법의 보호를 받으며 무단전재, 복사, 배포를 금합니다.
Copyright ⓒHinews. All rights reserved.
